Search research articles
Contact Us
Filters
Showing results (181-190 of 273) with videos related to
Page
of 28
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
May 31, 2021
Patterns of tau pathology identified with <sup>18</sup> F-MK-6240 PET imaging
William Charles Kreisl, Patrick J Lao, Aubrey Johnson, et al.
The Lancet. Neurology
|
January 8, 2013
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study
Maarten J Titulaer, Lindsey McCracken, Iñigo Gabilondo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 24, 2025
Basic Science and Pathogenesis
Jaclyn M Eissman, Min N Qiao, Vrinda Kalia, et al.
The New England Journal of Medicine
|
January 25, 2018
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Lawrence S Honig, Bruno Vellas, Michael Woodward, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 28, 2014
Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson's disease
Karen Nuytemans, Vanessa Inchausti, Gary W Beecham, et al.
The Lancet. Neurology
|
February 7, 2012
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
Reisa Sperling, Stephen Salloway, David J Brooks, et al.
International Journal of Impotence Research
|
January 10, 2002
Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism
R Berger, K Billups, G Brock, et al.
The New England Journal of Medicine
|
January 24, 2014
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease
Stephen Salloway, Reisa Sperling, Nick C Fox, et al.
The Lancet. Neurology
|
May 25, 2019
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial
Adam L Boxer, Irfan Qureshi, Michael Ahlijanian, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 1, 2024
Alzheimer's disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression
Ali S Ropri, Tiffany G Lam, Vrinda Kalia, et al.
Page
of 28
Search research articles
Search
Showing results (181-190 of 273) with videos related to
Sort By:
Page
of 28
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
May 31, 2021
Patterns of tau pathology identified with <sup>18</sup> F-MK-6240 PET imaging
William Charles Kreisl, Patrick J Lao, Aubrey Johnson, et al.
The Lancet. Neurology
|
January 8, 2013
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study
Maarten J Titulaer, Lindsey McCracken, Iñigo Gabilondo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 24, 2025
Basic Science and Pathogenesis
Jaclyn M Eissman, Min N Qiao, Vrinda Kalia, et al.
The New England Journal of Medicine
|
January 25, 2018
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Lawrence S Honig, Bruno Vellas, Michael Woodward, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
February 28, 2014
Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson's disease
Karen Nuytemans, Vanessa Inchausti, Gary W Beecham, et al.
The Lancet. Neurology
|
February 7, 2012
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
Reisa Sperling, Stephen Salloway, David J Brooks, et al.
International Journal of Impotence Research
|
January 10, 2002
Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism
R Berger, K Billups, G Brock, et al.
The New England Journal of Medicine
|
January 24, 2014
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease
Stephen Salloway, Reisa Sperling, Nick C Fox, et al.
The Lancet. Neurology
|
May 25, 2019
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial
Adam L Boxer, Irfan Qureshi, Michael Ahlijanian, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 1, 2024
Alzheimer's disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression
Ali S Ropri, Tiffany G Lam, Vrinda Kalia, et al.
Page
of 28